ACRVAcrivon Therapeutics, Inc.
This year, Acrivon Therapeutics has to prove it can deliver on its most promising asset: ACR-368. The next catalyst — the Q3 2026 earnings release on November 12 — is the first real test of whether the company can turn its pipeline into value, not just hype. If it clears that hurdle, the stock could rally to $3.00, with a bull target of $5.63 by December 3rd on Phase 2 ovarian cancer data. If it fails, the bear path drops to $2.00, but the odds are balanced. The real question isn’t whether the stock will go up or down — it’s whether Acrivon can show it’s not just another biotech with a lot of hope, but a company that can execute.
The Read
Acrivon's stock fell over 20% after Q1 2026 results and ACR-368 update due to ongoing cash burn and no immediate data, but surged 34.
The schedule
- Thu12Nov
Q3 2026 Earnings Release and Cash Runway Update
- Sun14Feb
Q4 2026 Earnings Release and Strategic Initiatives
- Wed12May
Q1 2027 Earnings Release and Clinical Trial Progress
- Wed11Aug
Q2 2027 Earnings Release and Product Pipeline Update
Past
- Wed12Aug
Actual outcome: Bull · $1.95 at outcome
ACRV beat earnings expectations with an EPS of -0.49 vs. estimate -0.49, signaling no miss. The company highlighted positive developments, including the Phase 2b interim analysis for ACR-368 and progress in the Phase 1/2 study for ACR-2316, which reinforced investor confidence in its clinical pipeline and long-term potential, driving the stock higher.
- Wed13May
Actual outcome: Bear · $1.57 at outcome
Acrivon reported Q1 2026 EPS of -$0.49, which met analyst estimates, and confirmed that its ACR-368 Phase 2b study is advancing toward an interim analysis in the second half of 2026. However, with no immediate clinical data to offset the company's ongoing cash burn and lack of revenue, the market reacted negatively, driving the stock down over 20% by the outcome date.